Drugs / AUTO2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03287804 | May 2017 → Sep 2019 | plasma cell myeloma | Autolus Limited | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AUTO2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03287804 ↗ |
| Known as | APRIL CAR T Cells | “AUTO2 (APRIL CAR T Cells) Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 15 x 10⁶ to 350 x 10⁶ APRIL...” NCT03287804 ↗ |
| Route | Intravenous | “receive AUTO2 intravenously as a single or split dose” NCT03287804 ↗ |